149 related articles for article (PubMed ID: 8931436)
1. Acute liver injury and octreotide.
González-Martín JA; Donnay S; Morillas J; Gómez-Aparicio C; Garcia-Cano J; Pérez-Vigara G; Roldán A
Am J Gastroenterol; 1996 Nov; 91(11):2434-5. PubMed ID: 8931436
[TBL] [Abstract][Full Text] [Related]
2. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
3. Successful pregnancy in an acromegalic women treated with octreotide.
Takeuchi K; Funakoshi T; Oomori S; Maruo T
Obstet Gynecol; 1999 May; 93(5 Pt 2):848. PubMed ID: 10912424
[No Abstract] [Full Text] [Related]
4. Octreotide.
Lamberts SW; van der Lely AJ; de Herder WW; Hofland LJ
N Engl J Med; 1996 Jan; 334(4):246-54. PubMed ID: 8532003
[No Abstract] [Full Text] [Related]
5. Successful pregnancy in a woman with acromegaly treated with somatostatin analog (octreotide) prior to surgical resection.
Mozas J; Ocón E; López de la Torre M; Suárez AM; Miranda JA; Herruzo AJ
Int J Gynaecol Obstet; 1999 Apr; 65(1):71-3. PubMed ID: 10390105
[TBL] [Abstract][Full Text] [Related]
6. Proliferation activity in somatotroph pituitary adenomas.
Delgrange E; Donckier J
Mayo Clin Proc; 1998 Oct; 73(10):1027-8. PubMed ID: 9787756
[No Abstract] [Full Text] [Related]
7. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
[TBL] [Abstract][Full Text] [Related]
8. [Octreotide-induced sinus bradycardia in a male patient with acromegaly].
Lima-Martínez MM; López-Méndez G; Mangupli R
Endocrinol Nutr; 2013 Oct; 60(8):e7-9. PubMed ID: 23415777
[No Abstract] [Full Text] [Related]
9. Octreotide LAR for the treatment of acromegaly.
Vallette S; Serri O
Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):783-93. PubMed ID: 18611118
[TBL] [Abstract][Full Text] [Related]
10. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
11. Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR.
Resmini E; Murialdo G; Giusti M; Boschetti M; Minuto F; Ferone D
J Endocrinol Invest; 2005 Feb; 28(2):166-9. PubMed ID: 15887864
[TBL] [Abstract][Full Text] [Related]
12. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
Harinarayan CV
J Indian Med Assoc; 2004 May; 102(5):258, 260-1. PubMed ID: 15636029
[TBL] [Abstract][Full Text] [Related]
13. Advances in the medical and surgical treatment of pituitary adenomas: the role of long-acting somatostatin analogs. Participants of the "Conference on Medical and Surgical Treatment of Pituitary Adenomas" (Zürich, 5th October, 1991).
Fahlbusch R; Giovanelli M; Buchfelder M; Losa M
J Endocrinol Invest; 1993 Jun; 16(6):449-60. PubMed ID: 8370920
[No Abstract] [Full Text] [Related]
14. Effective treatment of recurrent acromegaly with a long-active somatostatin analogue (sandostatin).
Miranda R; Zárate A; Ruíz Velasco G
Arch Invest Med (Mex); 1988; 19(4):445-8. PubMed ID: 3245759
[No Abstract] [Full Text] [Related]
15. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
16. Effect of long-term treatment with somatostatin analogue (SMS 201-995) on pituitary tumor shrinkage in acromegaly--report of two cases.
Mukada K; Uozumi T; Takechi A; Arita K; Yano T; Hirohata T; Onda J; Ohta M
Neurol Med Chir (Tokyo); 1992 Apr; 32(4):215-9. PubMed ID: 1378566
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial.
Thapar K; Kovacs KT; Stefaneanu L; Scheithauer BW; Horvath E; Lloyd RV; Li J; Laws ER
Mayo Clin Proc; 1997 Oct; 72(10):893-900. PubMed ID: 9379690
[TBL] [Abstract][Full Text] [Related]
18. [Hypophyseal thyrotropin adenomas at Yaounde (Cameroon). Analysis of two case reports: improvement with somatostatin analogue (SMS 201-995)].
Nouedoui C; Moukouri E; Juimo AG; Dongmo L; Zok FD; Tapko JB; Muna WF
Tunis Med; 1999 Mar; 77(3):154-8. PubMed ID: 10392035
[No Abstract] [Full Text] [Related]
19. Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature.
Erem C; Ersöz HO; Ukinç K; Avunduk AM; Hacihasanoglu A; Koçak M
Endocrine; 2006 Aug; 30(1):145-9. PubMed ID: 17185803
[TBL] [Abstract][Full Text] [Related]
20. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G
J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
